SABS · SAB Biotherapeutics, Inc.
$3.49
+0.04 (+1.16%)
At close · Jul 29
Market Cap
$263.80M
Shares
76.46M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
$13.27M
+138.9%
FY2025
Operating Margin
-3244.87%
-1544.3pp
FY2024
Diluted EPS
-$0.79
+78.5%
FY2025
Operating Cash Flow
-$44.78M
-30.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $0 | $1.32M | $2.24M | $23.9M | $60.88M | $55.24M | |
| $40.09M | $34.35M | $30.25M | $16.52M | $36.44M | $57.18M | $27.91M | |
| $18.09M | $14.6M | $13.98M | $23.8M | $16.38M | $17.09M | $6.77M | |
| $2.97M | $2.99M | $4.71M | $3.65M | $3.17M | $1.49M | $383.14K | |
| $58.18M | $48.95M | $44.23M | $40.31M | $52.82M | $74.27M | $34.68M | |
| -$58.18M | -$48.95M | -$42.91M | -$38.08M | -$28.92M | -$13.39M | $20.56M | |
| — | — | -3244.87% | -1700.56% | -120.97% | -22% | 37.22% | |
| -$55.21M | -$45.96M | -$38.2M | -$34.42M | -$25.75M | -$11.9M | $20.94M | |
| $233.84K | $240.66K | $318.4K | $315.28K | $301.58K | $294.46K | $469.15K | |
| $57.78M | $62.23M | $8.81M | -$4.12M | $10.2M | -$3.75M | $3996 | |
| — | $13.27M | — | -$42.19M | -$18.72M | -$17.14M | $20.12M | |
| — | $0 | $0 | $0 | $25.63K | $0 | $0 | |
| -$398.43K | $13.27M | -$34.11M | -$42.19M | -$18.74M | -$17.14M | $20.12M | |
| — | — | -2579.03% | -1884.5% | -78.4% | -28.16% | 36.42% | |
| -$9.41M | $4.26M | -$34.11M | -$42.19M | -$18.74M | — | $20.12M | |
| -$509.6K | $13.6M | -$34.27M | -$42.17M | -$18.74M | — | — | |
| USD/shares | — | $0.22 | -$3.68 | -$7.64 | -$4.31 | -$6.30 | $7.90 |
| USD/shares | — | -$0.79 | -$3.68 | -$7.64 | -$4.31 | -$6.30 | $7.40 |
| shares | — | 19.31M | 9.26M | 5.52M | 4.35M | 2.73M | 2.54M |
| shares | — | 61.34M | 9.26M | 5.52M | 4.35M | 2.73M | 2.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.45×
EV/EBIT
—
Peer median 11.37×
P/E (TTM)
—
Peer median 5.37×
Peer medians compare against the 316 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Grant | $23,904,181 | $60,876,078 | $55,237,759 |